Trodelvy 180 mg Powder for concentrate for solution for infusion Vial
Product Overview
Trodelvy 180 mg Powder for concentrate for solution for infusion Vial is a specialized prescription medication. It is widely available on leading pharmaceutical platforms such as Nahdi Online, , and . This medication is specifically designed for particular oncology treatments. It contains Sacituzumab Govitecan, an advanced antibody-drug conjugate. Trodelvy is manufactured by the reputable pharmaceutical company, Gilead Sciences.
What is Trodelvy?
Trodelvy (Sacituzumab Govitecan) represents an advanced targeted therapy. It is used in the treatment of certain aggressive types of cancer. This medication is specifically indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Eligible patients must have received two or more prior systemic therapies, with at least one for metastatic disease. Trodelvy is also approved for hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer. Furthermore, it is approved for metastatic urothelial cancer. This innovative medication operates by delivering a potent chemotherapy agent directly to cancer cells that express the Trop-2 protein. This targeted approach helps in minimizing systemic toxicity while enhancing therapeutic efficacy.
Benefits of Use
- Targets Trop-2 expressing cancer cells, providing a precise therapeutic approach.
- Demonstrated improvement in progression-free survival (PFS) and overall survival (OS) in eligible patient populations.
- Offers a critical treatment option for patients with difficult-to-treat metastatic triple-negative breast cancer and other advanced cancers.
- Designed to reduce systemic exposure to chemotherapy compared to traditional methods.
How to Use
- Trodelvy is administered by a qualified healthcare professional via intravenous (IV) infusion in a clinical setting.
- The specific dosage, infusion rate, and schedule will be determined by your treating physician based on your medical condition, body surface area, and response to therapy.
- Pre-medication, such as antiemetics and antihistamines, may be administered prior to infusion to prevent or reduce infusion-related reactions and nausea/vomiting.
- Patients should be monitored closely during and after infusion for any signs of adverse reactions.
- Do not self-administer Trodelvy; always follow the instructions of your healthcare provider.
Caution & Warnings
- Severe Neutropenia: Trodelvy can cause severe and life-threatening neutropenia. Blood counts should be monitored frequently during treatment.
- Severe Diarrhea: Severe diarrhea, including dehydration and electrolyte imbalances, has been reported. Monitor patients for diarrhea and manage promptly.
- Hypersensitivity/Infusion-Related Reactions: Infusion-related reactions, including severe anaphylactic reactions, can occur. Medications to manage such reactions should be available.
- Nausea and Vomiting: May be severe. Administer antiemetic prophylaxis as recommended by your physician.
- Embryo-Fetal Toxicity: Trodelvy can cause fetal harm when administered to a pregnant woman. Advise patients of reproductive potential to use effective contraception during treatment and for a specified period after the last dose.
- Renal and Hepatic Impairment: Use with caution in patients with pre-existing moderate to severe renal or hepatic impairment.
Ingredients
- Active Ingredient: Sacituzumab Govitecan 180 mg
- Excipients: The powder for concentrate typically includes inactive ingredients such as Trehalose Dihydrate, Polysorbate 80, Citric Acid Monohydrate, and Sodium Citrate Dihydrate, which help maintain the stability and solubility of the drug.
Product Details
- Form: Powder for concentrate for solution for infusion
- Strength: 180 mg per vial
- Manufacturer: Gilead Sciences
- Drug Type: Prescription Only Medicine (POM), Oncology
- Administration Route: Intravenous Infusion
- Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
| Gtin | 2601233183 |
|---|---|
| Recommended Sale Price | 4836.95 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | SACITUZUMAB GOVITECAN |
| SFDA Reg. No | 2601233183 |
| IBC | 2601233183 |
| Drug Type | Prescription Only Medicine |
| Scientific Name | Sacituzumab Govitecan |
| Strength | 180 mg |
| Strength Unit | mg |
| Form | Powder for concentrate for solution for infusion |
| Admin Route | Intravenous Infusion |
| Size | 1 |
| Size Unit | Vial |
| Package Types | Vial |
| Package Size | 1 Vial |
| Storage conditions | Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Refrigerator Storage | Yes |
